Katsuya Hirano

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC

Yasuto Yoneshima, Satoshi Morita, Masahiko Ando et al. · Journal of Thoracic Oncology · 2021 · 101 citations · Full text

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya et al. · Investigational New Drugs · 2019 · 54 citations

Metastatic Sites, High Pd-l1 Expression, Medicine +7

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)

Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya et al. · Investigational New Drugs · 2019 · 52 citations

First-line Therapy, Medicine, Least 50 +7

Searching for very early precursors of autism spectrum disorders: the Hamamatsu Birth Cohort for Mothers and Children (HBC)

Kenji J. Tsuchiya, Kaori Matsumoto, Shiro Suda et al. · Journal of Developmental Origins of Health and Disease · 2010 · 47 citations

Autism Spectrum Disorders, Education, Neurodiversity +17